This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Small-Cap Winners and Losers

Research Frontiers (REFR - Get Report) was rocketing nearly 30% after Japan's Hitachi Chemical began shipping light-control film using Research Frontiers' suspended-particle-device technology to Innovative Glass. Both Hitachi and Innovative Glass are licensing the technology -- which allows for electric control of light and heat passing through windows and doors, among other things -- from the Woodbury, N.Y., company. Shares were trading up $1.84 to $8.23.

New Jersey's NexMed (NEXM) soared after the drugmaker announced that collaborator Novartis (NVS) began dosing test subjects for advanced-phase testing on its nail fungus treatment, NM100060, for which NexMed is handling a number of developmental and commercial responsibilities. NexMed was gaining 36 cents, or 35.4%, to $1.37. Switzerland-based Novartis was recently trading up 68 cents, or 1.2%, to $58.37.

Tollgrade Communications, (TLGD) which makes remote system-monitoring products, surged after narrower fourth-quarter earnings nonetheless smashed Wall Street estimates. Excluding a restructuring charge, the Pittsburgh-based company had a profit of $1.9 million, or 14 cents a share, on sales that wilted 9% to $16.6 million. On a per-share basis, this flat-lines with last year's $4.4 million in income, but analysts polled by Thomson Financial were looking for 7 cents a share on sales of $16.7 million. Shares were gaining $1.60, or 15.9%, to $11.66.

Magma Design Automation (LAVA), which develops electronic design automation software, jumped after it said a U.S. District Court ruled Synopsys (SNPS) and IBM (IBM) jointly own two of the three patents at issue in the litigation between Magma and Synopsys. The court ruled that the third patent is owned solely by Synopsys. IBM is one of Magma's technology partners.

Synopsys said the court determined that Magma doesn't have any ownership interest in the patents or in any of the fixed-timing inventions that are at the core of the claims against Magma. Magma has also been ordered to transfer to Synopsys and IBM a number of additional patent applications that had been pending throughout the world, Synopsys said. Magma was rising $1.52, or 17.9%, to $10.02. Synopsys slipped 31 cents, or 1.2%, to $26.29. IBM was down $1.03, or 1%, to 98.12, in recent trading.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CNQR $128.78 -0.02%
EGHT $8.72 3.80%
REFR $5.92 -3.00%
AAPL $124.25 -0.14%
FB $81.66 -0.67%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs